Advertisement

Acute and repeated toxicological study of Myelophil, an ethanol extract of a mixture of Astragali Radix and Salviae Miltiorrhizae Radix, in beagle dogs

  • Jin-Yong Joung
  • Jin-Seok Lee
  • Jung-Hyo Cho
  • Dong-Soo Lee
  • Chang-Gue SonEmail author
Open Access
Research article
  • 92 Downloads
Part of the following topical collections:
  1. Basic Research

Abstract

Background

To evaluate the pharmaceutical safety of Myelophil, an ethanol extract of a mixture of Astragali Radix and Salviae Miltiorrhizae Radix, using both acute and repeated toxicological studies.

Methods

A total of 40 beagle dogs (20 each male and female) were fed doses up to 5,000 mg/kg for the acute study and up to 1,250 mg/kg for the 13-week repeated dose toxicological study. Adverse effects were examined intensively by comparing the differences between normal and drug-administered groups using clinical signs, autopsies, histopathological findings, hematology, urinalysis, and biochemical analysis.

Results

No mortality or drug-related clinical signs were observed in the Myelophil-treated groups, except for vomiting due to an excessive dose (5,000 mg/kg). Likewise, in the repeated toxicity test, compound-colored stools in the Myelophil-treated groups and soft stools in all groups, including the control, were observed. No drug-related abnormalities were found in the histopathology, hematology, urinalysis, and biochemical analyses for any doses of Myelophil.

Conclusion

These results support the safety of Myelophil with a no observed adverse effect level (NOAEL) of 1250 mg/kg in beagle dogs, which corresponds to a human equivalent dose (HED) of 694 g/kg.

Keywords

Myelophil Astragali Radix Salviae Miltiorrhizae Radix Safety Toxicological study NOAEL HED 

Abbreviations

ALD

Approximate lethal dose

CBC

Complete blood counts

FDA

U.S. Food and Drug Administration

HED

Human equivalent dose

KFDA

Korea Food and Drug Administration

MYP

Myelophil

NOAEL

No observed adverse effect level

SD rat

Sprague Dawley rat

TCM

Traditional Chinese medicine

UHPLC

Ultra-high-performance liquid chromatography

Background

The use of complementary and alternative medicine is increasing worldwide, and many medicinal plants are being used for disease treatment and health improvement purposes [1, 2]. Since medicinal plants are derived from nature and have been used for a long time, they are generally regarded as safe [3]. However, recent studies have warned about the safety of medicinal plants [4, 5]. In particular, the potential hepatotoxicity and renal toxicity of medicinal plants have been reported [6, 7].

Myelophil is a 1:1 mixture of the 30% ethanol extracts of Astragali radix and Salvia radix and is used clinically to treat patients with chemotherapy/radiation therapy-induced myelosuppression or chronic fatigue-related disorders [8, 9]. In particular, in addition to the results in an animal model, Myelophil showed anti-fatigue effectiveness in a clinical trial on idiopathic chronic fatigue [9, 10]. In addition, a previous preclinical study showed partial evidence for the safety of Myelophil from a sub-chronic toxicological study using Sprague Dawley (SD) rats [11]. Regarding the wide spectrum of Myelophil applications with respect to age, period and subjects, there is a strong demand for further evidence on the safety of Myelophil. In particular, comparisons with non-rodent-derived studies are needed due to the limitations of rodent-based toxicity studies [12].

Individually, both Astragali radix and Salvia radix, which compose Myelophil, have been reported to be safe in several toxicological studies [13, 14]. These medicinal plants are known as two representative herbs used to treat Qi- and Blood- disorders, respectively, and they are frequently prescribed together in a formula in clinical practice [9]. However, to date, no non-rodent animal studies have been conducted to evaluate the safety of the combination.

Myelophil is an anti-fatigue therapeutics candidate, which its effects will be evaluated via clinical study in the future. In order to provide the safety evidence according to Korea Food and Drug Administration (KFDA), this study aimed to evaluate the tolerance range in a single acute study and to estimate the no observed adverse effect level (NOAEL) of Myelophil using a 13-week repeated toxicological test on beagle dogs.

Materials and methods

Preparation and fingerprinting of Myelophil

Myelophil was prepared in powder form by Kyung-Bang Pharmacy (Incheon, Korea) as follows according to the approved good manufacturing practice (GMP) guidelines of the KFDA [15]. Myelophil is the 1:1 mixture of Astragali Radix (Astragalus membranaceus Bunge, cultivated in Jecheon, South Korea Ser. No. 20101106-JC-HG) and Salviae Miltiorrhizae Radix (Salvia miltiorrhiza Bunge, cultivated in Hebei, China; Ser. NO. 20110302-CHN-DS). These two herbal materials were purchased from Daeyeon Pharmacy (Supplier of standardized herbs, Incheon, Korea), and they were confirmed by expert for herbology who is an herbal pharmacist. Myelophil was extracted using 30% ethanol for 20 h at 80 °C and the final product obtained with a yield of 20.52% (w/w) was stored for future use. To confirm the reproducibility of Myelophil’s components, ultra-high-performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS, Thermo Scientific, San Jose, CA, USA) method was re-conducted as described previously [16] (Fig. 1a). Liquid chromatography-mass spectrometry (LC/MS, LTQ ORbitrap XL linear ion-trap MS system, Thermo Scientific, San Jose, CA, USA) was also performed on the Myelophil as well as 4 reference compounds (astragaloside IV and formononetin for Astragali Radix and salvianolic acid B and rosmarinic acid for Salviae Miltiorrhizae Radix, respectively) for quantitative analysis as previously described [17] (Fig. 1b).
Fig. 1

UHPLC and LC/MS chromatogram of Myelophil. Myelophil and reference compounds were subjected to UHPLC analysis (a). Myelophil and four major compounds (Astragaloside IV and Formononetin for Astragali radix and Salvianolic acid B and Rosmarinic acid for Salviae Miltiorrhizae radix) were quantified by LC/MS (b)

Animals

A total of 40 beagle dogs (20 males and 20 females) were purchased from Woojung BSG (Gyeonggi-do Suwon, Korea) and used for the study. Each dog was acclimated to conditions in a stainless-steel mesh box (700 mm W × 750 mm L × 750 mm H) for 3 weeks and was subjected to routine examination daily. The environment was maintained at 21.9 ± 0.8 °C with a 12-h light/dark cycle, and the air was exchanged between 10 and 15 times/h. Each dog received 300 g/day of a standard dry diet (Biopia; Gyeoggi-do Gunpo, Korea) and had free access to automatically filtered tap water that had undergone a purification process. At the time of drug administration, the dogs averaged 6–7 months of age and ranged from 5.52 to 6.72 kg for males and 5.04 to 6.42 kg for females. All animals were checked for health before the drug administration. This study was conducted in Korea Conformity Laboratories (KCL, Incheon, Korea), an authorized institute for toxicological research, and adhered to the Testing Guidelines of KFDA [18]. Experts including histopathologist, animal specialist, and drug manager confirmed that this toxicity study was performed correctly.

Acute toxicity

After an overnight fast, one male and one female in each of the four groups received 5,000 mg/kg, 2,500 mg/kg, 1,250 mg/kg, and 0 mg/kg doses of Myelophil using an oral capsule (single dose). Clinical signs were observed for 6 h after drug administration; thereafter, daily mortality and symptoms were observed for 2 weeks. Body weights were measured 1, 3, 7, and 14 days after administration, and necropsy was performed on day 14.

Repeated toxicity

For the repeated toxicity test, 32 beagles (16 male and 16 female) were dived into 4 groups (Control: 10 dogs at 0 mg/kg, low dose: 6 dogs at 312.5 mg/kg, middle dose: 6 dogs at 625 mg/kg and high dose: 10 dogs at 1,250 mg/kg). Over 13 weeks, each dog was administered Myelophil by using an oral capsule once a day. In the two groups with 5 males and 5 females (1,250 mg/kg and 0 mg/kg), the extra 2 males and 2 females of each group were set up as recovery groups for 4 weeks.

Clinical signs of toxicity were checked once a day, and body weights and feed intake were measured once a week. Before the drug administration and within 1 week prior to the necropsy, ophthalmological examination, electrocardiography, urinalysis, hematological, and various biochemical parameters were performed. After necropsy, the external findings were recorded, and all organs, such as abdominal organs, thoracic organs and brain, were weighed. Histopathological examinations were performed for the following organs: brain, pituitary, heart, lungs, liver, gallbladder, kidney, bladder, mesenteric lymph nodes, thymus, spleen, pancreas, salivary glands, submandibular lymph nodes, thyroid, adrenal gland, esophagus, aorta, Spinal cord, sciatic nerve, skeletal muscles, skin, mammary gland, eye ball, stomach, pancreas, thymus, thyroid gland, parathyroid gland, duodenum, jejunum, ileum, appendix, colon, rectum, femur, sternum, trachea, tongue, prostate gland, testis, epididymis, ovary, bladder, uterus, and vagina.

Statistical analysis

The analysis of the continuous data (organ weight, food intake, and hematological and biochemical parameters) was performed using one-way ANOVA. Statistical differences between the groups were analyzed using Dunnett’s multiple comparison test [19]. Dunnett’s t-test was performed when the dispersion was not homogeneous. The analysis of discontinuous data used the chi-square test after re-input of data after scale conversion. All analyses were performed using SPSS 12.0 K program, which is a widely used statistical package.

Results

Acute toxicity

No animals died during the test. In female animals, vomiting was observed on the day of administration in the 5,000 mg/kg group and the day after administration in the 2,500 mg/kg and 1,250 mg/kg groups. Compound-colored stools were observed on the 2nd day after administration in the 2,500 mg/kg group. These symptoms were also observed in the male animals; vomiting on the day of administration in the 5,000 mg/kg group and compound-colored stools in the 2,500 mg/kg group until day 4 after administration. There were no changes in body weight during the study period, and no abnormal lesions were observed at necropsy (Table 1).
Table 1

Summary of the acute toxicity test in beagle dogs

MYP (mg/kg)

0

1250

2500

5000

Number (M/F)

2 (1/1)

2(1/1)

2(1/1)

2 (1/1)

Mortality

Vomiting on the day of

administration

++ (M, F)

Vomiting on the day after of

administration

+ (F)

+ (F)

Compound-colored stool

+ (M)

Body weight change

Necropsy findings

NAD

NAD

NAD

NAD

Beagle dogs in each group were fed Myelophil (MYP). Clinical signs were observed for 6 h after drug administration; thereafter, daily mortality and symptoms were observed for 2 weeks. At the end of the experiment, necropsy was performed

M Male, F Female, NAD No abnormality detected; −: Absent; +: Slight; ++: Moderate

Repeated toxicity

Clinical signs and mortality

No deaths were observed in any group during the study period. Drug compound-colored stools were observed in the 625 and 1,250 mg/kg groups, which appeared to be dose-related in both males and females. Soft stools were observed in all the dose groups (including the control) in a dose-related pattern in both males and females. Anorexia was sporadically observed all groups but without a dose-correlation (Table 2).
Table 2

Summary of the repeated toxicity test in beagle dogs

MYP (mg/kg per day)

0

312.5

625

1250

Number (M/F)

10 (5/5)

6(3/3)

6(3/3)

10 (5/5)

Mortality

Anorexia

−+

−+

−+

−+

Soft stool

+

+

++

+++

Compound-colored stool

++

+++

Food intake

NAD

NAD

NAD

NAD

Ophthalmological findings

NAD

NAD

NAD

NAD

Relative organ weight

NS

NS

NS

NS

Necropsy findings

NAD

NAD

NAD

NAD

Beagle dogs in each group were fed MYP, and the clinical symptoms, including mortality, were monitored for 13 weeks. At the end of the experiment, ophthalmological, necropsy-based examinations were performed

NAD No abnormality detected, NS Not significant; −: Absent; +: Slight; ++: Moderate; +++: Severe; −+: Sporadically detected

Weight change and feed intake

Body weight increased gradually during the study period in all groups. However, there were no significant differences in the body weights or food intake in groups administered with Myelophil compared to the controls during the study period (Fig. 2).
Fig. 2

Body weight changes of dogs after 13 weeks. There were no significant differences in the body weight in the groups administered with Myelophil compared with the control group during the study period

Hematologic tests

At the 13th week of administration, no abnormal parameters were observed in the complete blood counts (CBC), including the blood-clotting time tests, in male or female animals of any group (Table 3).
Table 3

Hematological analysis after administration of Myelophil for 13 weeks

MYP (mg/kg)

Male

Female

0

312.5

625

1250

0

312.5

625

1250

Number

5

3

3

5

5

3

3

5

WBC (103/μL)

9.4 ± 0.8

10.6 ± 2.2

10.0 ± 2.1

8.4 ± 1.3

7.6 ± 0.7

8.1 ± 1.6

8.7 ± 1.6

9.0 ± 1.7

WBC Differential Counts (%)

 NE

52.0 ± 3.5

54.3 ± 4.6

49.3 ± 8.7

62.1 ± 3.0

50.3 ± 8.1

55.5 ± 5.2

50.5 ± 4.0

50.1 ± 10.2

 LY

36.8 ± 6.2

37.0 ± 4.2

41.5 ± 11.4

38.8 ± 2.4

39.2 ± 7.7

35.3 ± 6.7

41.9 ± 3.9

42.1 ± 10.5

 MO

4.9 ± 1.2

4.0 ± 0.7

4.4 ± 1.9

4.5 ± 1.3

4.5 ± 0.8

5.0 ± 1.4

4.5 ± 0.9

4.0 ± 1.0

 EO

5.8 ± 3.3

4.2 ± 1.1

4.3 ± 1.2

4.1 ± 0.9

5.3 ± 2.9

3.6 ± 1.2

2.3 ± 0.7

3.2 ± 1.3

 BA

0.3 ± 0.2

0.4 ± 0.1

0.3 ± 0.2

0.4 ± 0.1

0.6 ± 0.2

0.4 ± 0.3

0.6 ± 0.2

0.5 ± 0.2

RBC (106/μL)

7.3 ± 0.6

7.8 ± 0.3

7.5 ± 0.6

8.0 ± 0.3

8.3 ± 0.6

8.2 ± 0.8

8.4 ± 0.7

8.3 ± 0.7

Hemoglobin (g/dL)

16.3 ± 0.9

16.4 ± 0.6

16.0 ± 1.1

17.1 ± 0.9

18.5 ± 1.1

17.6 ± 1.2

18.9 ± 1.6

18.3 ± 1.2

Hematocrit (%)

49.6 ± 2.6

50.7 ± 1.4

49.7 ± 3.1

52.8 ± 2.4

57.4 ± 3.7

55.4 ± 3.8

57.6 ± 4.5

56.4 ± 3.9

MCV (fL)

68.2 ± 2.5

64.8 ± 2.1

66.7 ± 2.2

66.1 ± 3.2

69.0 ± 1.4

67.7 ± 1.8

68.4 ± 1.1

68.4 ± 1.7

MCH (pg)

22.5 ± 0.7

20.9 ± 0.8

21.4 ± 1.1

21.4 ± 1.3

22.3 ± 0.5

21.5 ± 0.7

22.4 ± 0.0

22.2 ± 0.7

MCHC (g/dL)

32.9 ± 0.2

32.3 ± 0.3

32.1 ± 0.5

32.4 ± 0.5

32.3 ± 0.4

31.7 ± 0.5

32.8 ± 0.5

32.4 ± 0.3

RDW (%)

14.1 ± 0.6

14.4 ± 0.2

14.7 ± 1.5

14.6 ± 0.9

13.4 ± 0.9

13.6 ± 0.4

13.8 ± 0.6

14.2 ± 1.1

Platelet (103/μL)

327.0 ± 44.2

326.3 ± 68.3

380.7 ± 35.6

349.6 ± 73.9

301.8 ± 54.0

352.7 ± 87.8

329.0 ± 62.4

326.4 ± 52.9

MPV (fL)

16.3 ± 1.4

17.8 ± 1.1

17.0 ± 0.3

16.6 ± 1.3

16.5 ± 1.1

16.4 ± 2.4

17.2 ± 0.8

16.6 ± 0.7

Reticulocytes (%)

1.1 ± 0.3

1.1 ± 0.2

1.1 ± 0.6

1.0 ± 0.3

0.8 ± 0.2

1.0 ± 0.3

1.1 ± 0.3

0.9 ± 0.2

PT (sec)

6.0 ± 0.2

6.00 ± 0.1

6.0 ± 0.2

6.0 ± 0.2

6.0 ± 0.2

6.1 ± 0.1

6.3 ± 0.3

6.1 ± 0.2

aPTT (sec)

12.3 ± 0.7

12.1 ± 0.3

12.2 ± 1.0

12.2 ± 0.8

12.8 ± 1.3

12.9 ± 0.8

11.5 ± 1.5

12.5 ± 0.6

After administration of MYP for 13 weeks, hematology was analyzed to compare the MYP-treated groups to the control group

WBC White blood cell, NE Neutrophil, LY Lymphocyte, MO Monocyte, EO Eosinophil, BA Basophil, RBC Red blood cell, MCV Mean corpuscular volume, MCH Mean corpuscular hemoglobin, MCHC Mean corpuscular hemoglobin concentration, RDW Red cell distribution width, MPV Mean platelet volume, PT Prothrombin time, APPT Activated partial thromboplastin time

Biochemical tests

At the 13th week of administration, the serum concentrations of sodium and chloride were significantly decreased in the 312.5 and 1,250 mg/kg groups of females compared to the control group (P < 0.05). Those findings were not observed in the male groups. Other abnormalities in the biochemical parameters were not observed in the Myelophil-administered groups (Table 4).
Table 4

Serum chemistry analysis after administration of Myelophil for 13 weeks

MYP (mg/kg, Number)

Male

Female

0 (5)

312.5 (3)

625 (3)

1250 (5)

0 (5)

312.5 (3)

625 (3)

1250 (5)

AST (IU/L)

38.4 ± 9.6

48.0 ± 7.2

42.3 ± 12.1

47.8 ± 6.8

40.6 ± 5.1

44.0 ± 2.0

47.3 ± 16.4

44.0 ± 6.0

ALT (IU/L)

40.0 ± 10.2

37.7 ± 9.1

31.3 ± 6.0

47.8 ± 19.8

36.8 ± 5.7

37.0 ± 5.6

40.0 ± 14.8

40.4 ± 10.4

ALP (IU/L)

334.8 ± 97.7

494.0 ± 103.5

330.3 ± 116.6

345.2 ± 60.2

336.8 ± 120.0

219.3 ± 50.5

295.0 ± 10.4

289.4 ± 79.7

BUN (mg/dL)

16.6 ± 2.4

17.4 ± 2.6

15.0 ± 2.3

14.3 ± 1.6

17.4 ± 4.8

17.0 ± 1.7

14.4 ± 2.7

14.4 ± 2.4

Creatinine (mg/dL)

0.72 ± 0.03

0.66 ± 0.11

0.77 ± 0.06

0.82 ± 0.10

0.72 ± 0.13

0.63 ± 0.03

0.75 ± 0.05

0.72 ± 0.08

Glucose (mg/dL)

89.8 ± 7.3

79.3 ± 3.8

84.3 ± 7.8

84.4 ± 9.5

86.6 ± 4.0

84.7 ± 3.1

92.0 ± 3.0

86.4 ± 9.6

Total cholesterol (mg/dL)

184.0 ± 35.2

169.7 ± 27.2

151.7 ± 19.7

170.6 ± 37.3

160.0 ± 28.9

165.7 ± 34.6

150.3 ± 3.2

162.6 ± 32.2

Total protein (g/dL)

5.5 ± 0.4

5.6 ± 0.2

5.6 ± 0.4

5.9 ± 0.3

5.8 ± 0.3

5.7 ± 0.4

5.8 ± 0.2

5.8 ± 0.4

CPK (U/L)

242.6 ± 45.3

372.0 ± 152.2

307.0 ± 77.2

369.2 ± 122.9

256.0 ± 56.2

319.0 ± 79.7

362.3 ± 249.4

256.0 ± 75.6

Albumin (g/dL)

2.6 ± 0.2

2.7 ± 0.1

2.6 ± 0.1

2.8 ± 0.1

2.7 ± 0.3

2.7 ± 0.3

2.9 ± 0.2

2.9 ± 0.2

Total bilirubin (mg/dL)

0.04 ± 0.01

0.06 ± 0.02

0.04 ± 0.02

0.06 ± 0.03

0.07 ± 0.02

0.05 ± 0.02

0.06 ± 0.03

0.07 ± 0.02

A/G ratio

0.89 ± 0.19

0.94 ± 0.02

0.87 ± 0.14

0.88 ± 0.07

0.88 ± 0.07

0.93 ± 0.09

0.98 ± 0.05

0.99 ± 0.04

Triglyceride (mg/dL)

24.4 ± 3.6

44.0 ± 17.8

23.0 ± 4.0

30.4 ± 9.8

28.0 ± 2.9

28.0 ± 4.4

31.3 ± 6.1

30.2 ± 9.3

Calcium (mg/dL)

10.3 ± 0.4

10.4 ± 0.4

10.2 ± 0.5

10.6 ± 0.5

10.3 ± 0.4

10.2 ± 0.5

10.3 ± 0.4

10.2 ± 0.6

Inorganic phosphorus (mg/dL)

6.0 ± 0.7

6.0 ± 0.1

5.7 ± 0.7

5.8 ± 0.6

5.2 ± 0.4

4.9 ± 0.3

5.1 ± 1.3

4.8 ± 0.3

Chloride (mmol/L)

112.4 ± 1.5

112.3 ± 0.6

110.7 ± 1.5

111.0 ± 2.0

109.8 ± 10.3

107.0 ± 1.7*

109.7 ± 1.2

108.6 ± 0.9*

Sodium (mmol/L)

149.2 ± 1.3

148.0 ± 0.0

148.0 ± 1.0

148.0 ± 2.4

146.4 ± 1.5

144.0 ± 1.0*

148.0 ± 1.7

145.8 ± 0.8*

Potassium (mmol/L)

5.3 ± 0.3

5.4 ± 0.2

5.4 ± 0.2

5.7 ± 0.2

5.0 ± 0.4

5.3 ± 0.2

5.3 ± 0.2

5.1 ± 0.2

After the administration of MYP for 13 weeks, the serum chemistry was analyzed and compared to the control group

The data were expressed as the means ± sd

AST Aspartate aminotransferase, ALT Alanine aminotransferase, ALP Alkaline phosphatase, BUN Blood urea nitrogen, CPK Creatine phosphokinase, A/G ratio Albumin globulin ratio

*A statistical significance was considered if P < 0.05 compared with the vehicle control

Urinalysis

At the 13th week of administration, occult blood was increased in a statistically significant manner in 312.5 mg/kg males compared with the control group, and a statistically significant decrease was observed in the 312.5, 625, and 1,250 mg/kg females compared to the control group. These changes had no dose-relatedness or male-to-female correlations. No other abnormal parameters were observed in the urinalysis in the male or female animals of all groups (data not shown).

Gross autopsy findings

Adhesion between the left lobe and the medial lobe of liver was observed in 1 animal in the 625 mg/kg group, but there was no dose correlation or histopathological abnormality. No other abnormalities associated with the administration of Myelophil were observed. No changes associated with test drug administration were observed in organ weight. No abnormalities in either eye examination or electrocardiography were observed in any group before or after the test (data not shown).

Histopathologic examinations

In all of the Myelophil-treated groups and control group, infiltrations of inflammatory cells in several organs (liver, lung, thyroid, testicle), white pulp atrophy of the spleen, vacuolization in interstitium of the kidney, degranulation in the thymus, and mineral deposition in the kidney were observed sporadically. All of these abnormalities were infrequent and were not related to the dose (Additional file 1: Table S1). The normal histopathological findings in the main organ (liver, lung and kidney) were shown in Fig. 3.
Fig. 3

Histopathological findings. Representative pictures from H&E staining sections of the liver, lung, and kidney. No significant abnormalities associated with drug was observed

Discussion

Our previous studies partially proved the safety of Myelophil in rats [11]. Rodent-derived studies are generally thought to provide only limited information on the adverse effects of drugs in humans [20]. In preclinical studies of drugs, the U.S. Food and Drug Administration (FDA) recommended that acute and repeated toxicity testing should be conducted in at least two mammalian species, including a non-rodent species [21]. In this study, we therefore evaluated the toxicity of Myelophil using beagle dog-based acute and repeated toxicological tests. Regarding the duration for repeated dose toxicity studies, the FDA generally recommends the same duration as is used for clinical purposes but a longer period than that required for the authorization of marketing [22]. For drugs used for more than 2 weeks and less than 1 month, FDA recommends a 3-month toxicity test in non-rodent. The common prescription-period of Myelophil is 4-week; therefore we designed a 13-week repeated toxicological test in our study.

Myelophil is a mixture of Astragali radix and Salvia radix extracts that has been prescribed to a wide spectrum of patients complaining of chronic fatigue and bone marrow dysfunctions in Daejeon University Hospital since 2002. This formula (the combination of Astragali radix and Salviae Radix extracts) was derived based on TCM theory to maintain the balance between Qi and Blood, and this combination is supported by experimental data that showed that it improved bone marrow function [8]. Astragali radix is ​​a medicinal herb that TCM indicates enhances Qi [23] and is reported to have immunomodulatory, anti-aging and antitumor effects [24, 25, 26]. Salviae Radix is a representative ​​herb that is used in TCM to treat blood-related disorders [27] and has been studied for antiplatelet aggregation, antioxidant, and anti-inflammatory effects [28, 29, 30].

In general, the clinical dose of Myelophil is 2,000–4,000 mg/day for a 60 kg adult. For evaluation of this clinical dose, we decided the maximum dose (1250 mg/kg) in repeated toxicological test based on NOAEL and safety factor (1/10) [31]. For the acute toxicity test, we determined the much larger maximum dose (5,000 mg/kg) to predict approximate lethal dose (ALD). In the present results, no beagle dog died following the single administration of 75 times the clinical dose of Myelophil (5,000 mg/kg), even in those dogs in which vomiting or drug compound-colored stool was observed. These symptoms were presumed to be due to the inability to absorb excess drug, and no abnormalities related to these side effects were found at the time of necropsy. Accordingly, the ALD was estimated to be greater than 2,500 mg/kg. The main purpose of a preclinical toxicological study is to evaluate the NOAEL value, which provides the safety range of a test drug in clinical practice [32]. The NOAEL values can be determined using a repeated toxicological test, and the resulting animal-derived value can be converted to a human equivalent dose (HED) [33]. These results provide key information on the range of clinical doses [34]. The calculation of the NOAEL is derived from the test material and metabolic rate in animals, and then the values can be converted into HED according to the comparison of body surface index and body weight between animals and human [35].

In our study, the 13-week repeated toxicity studies founded that the NOAEL of Myelophil in beagle dogs was greater than 1,250 mg/kg for both males and females. The soft compound-colored stools appeared to be a dose-related side effect in the testing groups; however, no weight changes or any histopathological findings were observed. These stool changes completely disappeared during the recovery period. Therefore, these effects were not considered to be toxicological changes but were presumed to be due to the excessive dose of testing materials. In the biochemical tests and urinalysis, electrolyte changes (sodium and chloride) and occult blood were observed in the test group. However, the range of changes was within the normal range and had no dose relatedness and no male-female correlation. These changes are likely to occur in normal beagle dogs and considered not to be related to Myelophil. Sporadic and rare histopathological findings, including the infiltration of inflammatory cells in the liver and lung, were observed in all groups including the control group, which would indicate accidental or spontaneous lesions independent of test substance administration. Abnormal stool formation and sporadic histopathological legions are generally common findings in repeated toxicological studies, even for edible materials [36, 37, 38]. The results described above may indicate that Myeloplil is very tolerable and safe for the tested animals, namely, beagle dogs.

In fact, several toxicological studies have been conducted on the individual herbs, Astragali radix or Salviae Radix. A subchronic toxicity study reported on the safety of Astragali radix extracted with an organic solvent in Sprague Dawley (SD) rats and beagle dogs up to 39.9 g/kg and 19.95 g/kg [39]. Another toxicological study (acute and subchronic) showed that the Salvia radix aqueous extract had a NOAEL of 5.76 g/kg in SD rats [14]. In these studies, the administration routes were intraperitoneal or intravenous injection, and their extraction conditions (organic solvent or water) were also different from our study (30% ethanol extract). Our toxicity study examined the combination of two common herbs and thus considered the possibility of drug-drug interactions in the toxicity, even though each drug is safe [40].

Conclusion

In summary, the NOAEL of Myelophil was over 1250 mg/kg in beagle dogs, which corresponded to an HED of 694 mg/kg. This result provides evidence for the safety of Myelophil at a clinical dose, which is an oral administration of 2,000–4,000 mg/day for a 60 kg adult. The present study provided the ALD and NOAEL values of Myelophil and toxicological information for the combination of Astragali radix and Salviae Radix.

Notes

Acknowledgements

None.

Authors’ contributions

JYJ and JSL both participated mainly in the design of the experiments and the manuscript preparation. JHC and DSL conducted the assays and analyses. CGS supervised the overall processes of the experiments and manuscript preparation. All authors read and approved the final manuscript.

Funding

This research was supported by Traditional Korean Medicine R&D Project, Ministry of Health & Welfare, South Korea (HI15C0112) and the Bio-medical Technology Development Project (2017M3A9E4065193).

Ethics approval and consent to participate

The beagle dogs were supplied by the Beijing Marshall Biotechnology (Beijing, China) and the study protocols were approved by the Institutional Animal Care and Use Committee of Korea Conformity Laboratories (Approval Number: GT11–00021). Animals were handled according to the guidelines by the National Institutes of Health and all efforts were made to alleviate animal suffering.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Supplementary material

12906_2019_2588_MOESM1_ESM.docx (18 kb)
Additional file 1: Table S1. Summary of histopathological findings. (DOCX 18 kb)

References

  1. 1.
    Eardley S, Bishop FL, Prescott P, Cardini F, Brinkhaus B, Santos-Rey K, et al. A systematic literature review of complementary and alternative medicine prevalence in EU. CMR. 2012;19(Suppl. 2):18–28.Google Scholar
  2. 2.
    Posadzki P, Watson LK, Alotaibi A, Ernst E. Prevalence of use of complementary and alternative medicine (CAM) by patients/consumers in the UK: systematic review of surveys. Clin Med. 2013;13:126–31.CrossRefGoogle Scholar
  3. 3.
    Karimi A, Majlesi M, Rafieian-Kopaei M. Herbal versus synthetic drugs; beliefs and facts. J Nephropharmacol. 2015;4:27–30.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4.  https://doi.org/10.3389/fphar.2013.00177.
  5. 5.
    Efferth T, Kaina B. Toxicities by herbal medicines with emphasis to traditional Chinese medicine. Curr Drug Metab. 2011;12:989–96.CrossRefGoogle Scholar
  6. 6.
    Teschke R, Wolff A, Frenzel C, Schulze J. Review article: herbal hepatotoxicity – an update on traditional Chinese medicine preparations. Aliment Pharmacol Ther. 2014;40:32–50.CrossRefGoogle Scholar
  7. 7.
    Asif M. A brief study of toxic effects of some medicinal herbs on kidney. Adv Biomed Res. 2012;1.  https://doi.org/10.4103/2277-9175.100144.CrossRefGoogle Scholar
  8. 8.
    Shin JW, Lee MM, Son JY, Lee NH, Cho CK, Chung WK, et al. Myelophil, a mixture of Astragali Radix and Salviae Radix extract, moderates toxic side effects of fluorouracil in mice. World J Gastroenterol. 2008;14:2323–8.CrossRefGoogle Scholar
  9. 9.
    Cho JH, Cho CK, Shin JW, Son JY, Kang W, Son CG. Myelophil, an extract mix of Astragali Radix and Salviae Radix, ameliorates chronic fatigue: a randomised, double-blind, controlled pilot study. Complement Ther Med. 2009;17:141–6.CrossRefGoogle Scholar
  10. 10.
    Lee J-S, Kim H-G, Han J-M, Kim Y-A, Son C-G. Anti-fatigue effect of Myelophil in a chronic forced exercise mouse model. Eur J Pharmacol. 2015;764:100–8.CrossRefGoogle Scholar
  11. 11.
    Jung J-M, Shin J-W, Son J-Y, Seong N-W, Seo D-S, Cho J-H, et al. Four-week repeated dose toxicity test for Myelophil in SD rats. J Korean Med. 2009;30(3):79-85. http://www.dbpia.co.kr/journal/articleDetail?nodeId=NODE02102497. Accessed 5 July 2019.
  12. 12.
    Box RJ, Spielmann H. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status. Arch Toxicol. 2005;79:615–26.CrossRefGoogle Scholar
  13. 13.
    Liu Y, Zhang Y, Sun Y, Zhang J. Long term toxicity experimental study of traditional Chinese herb Huangqi. Modern J Integr Tradit Chin West Med. 2009;18(29):3545–7.Google Scholar
  14. 14.
    Wang M, Liu J, Zhou B, Xu R, Tao L, Ji M, et al. Acute and sub-chronic toxicity studies of Danshen injection in Sprague-Dawley rats. J Ethnopharmacol. 2012;141:96–103.CrossRefGoogle Scholar
  15. 15.
    KFDA. Guidelines for Good Manufacturing Practice (GMP). Notification no. 2015–35. Seoul: Korea Food and Drug Administration; 2015. http://www.law.go.kr/LSW/admRulInfoP.do?admRulSeq=2100000021585&lsId=48642&chrClsCd=010202. Accessed 16 Sept 2018.
  16. 16.
    Lee J-S, Kim H-G, Han J-M, Son S-W, Ahn Y-cC, Son C-G. Myelophil ameliorates brain oxidative stress in mice subjected to restraint stress. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;3(39):339–47.CrossRefGoogle Scholar
  17. 17.
    Lee J-S, Kim H-G, Han J-M, Kim D-W, Yi M-H, Son S-W, et al. Ethanol extract of Astragali Radix and Salviae Miltiorrhizae Radix, Myelophil, exerts anti-amnesic effect in a mouse model of scopolamine-induced memory deficits. J Ethnopharmacol. 2014;153:782–92.CrossRefGoogle Scholar
  18. 18.
    KFDA. Guidelines for toxicity studies of drugs. Notification no. 2017–71. Seoul: Korea Food and Drug Administration; 2017. http://www.law.go.kr/admRulLsInfoP.do?admRulSeq=2100000097873.
  19. 19.
    Mukerjee H, Robertsonm T, Wright FT. A multiple comparison procedure for comparing several treatments with a control on JSTOR. J Am Stat Assoc. 1987;82:902–10.CrossRefGoogle Scholar
  20. 20.
    Morgan SJ, Elangbam CS, Berens S, Janovitz E, Vitsky A, Zabka T, et al. Use of animal models of human disease for nonclinical safety assessment of novel pharmaceuticals. Toxicol Pathol. 2013;41:508–18.CrossRefGoogle Scholar
  21. 21.
    FDA. Guidance for industry M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. 2010. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073246.pdf. Accessed 18 July 2018.Google Scholar
  22. 22.
    Denny KH, Stewart CW. Acute, subacute, subchronic, and chronic general toxicity testing for preclinical drug development. In: Faqi AS, editor. A comprehensive guide to toxicology in nonclinical drug development. 2nd ed. Michigan: Academic; 2016. p.96-7.Google Scholar
  23. 23.
    Liu J, Zhao Z, Chen H. Review of Astragali Radix. Chinese Herbal MEdicines. 2011;3:90–105.Google Scholar
  24. 24.
    Ryu M, Kim EH, Chun M, Kang S, Shim B, Yu Y-B, et al. Astragali Radix elicits anti-inflammation via activation of MKP-1, concomitant with attenuation of p38 and Erk. J Ethnopharmacol. 2008;115:184–93.CrossRefGoogle Scholar
  25. 25.
    Wang P, Zhang Z, Ma X, Huang Y, Liu X, Tu P, et al. HDTIC-1 and HDTIC-2, two compounds extracted from Astragali Radix, delay replicative senescence of human diploid fibroblasts. Mech Ageing Dev. 2003;124:1025–34.CrossRefGoogle Scholar
  26. 26.
    Lin YW, Chiang BH. Anti-tumor activity of the fermentation broth of Cordyceps militaris cultured in the medium of Radix astragali. Process Biochem. 2008;43(3):244–50.CrossRefGoogle Scholar
  27. 27.
    Wu B, Liu M, Zhang S. Dan Shen agents for acute ischaemic stroke. Cochrane Database Syst Rev. 2004;(4):CD004295.Google Scholar
  28. 28.
    Tang MK, Ren DC, Zhang JT, Du GH. Effect of salvianolic acids from Radix Salviae miltiorrhizae on regional cerebral blood flow and platelet aggregation in rats. Phytomedicine. 2002;9:405–9.CrossRefGoogle Scholar
  29. 29.
    Hung Y-C, Wang P-W, Pan T-L, Bazylak G, Leu Y-L. Proteomic screening of antioxidant effects exhibited by Radix Salvia miltiorrhiza aqueous extract in cultured rat aortic smooth muscle cells under homocysteine treatment. J Ethnopharmacol. 2009;124:463–74.CrossRefGoogle Scholar
  30. 30.
    Ma S, Zhang D, Lou H, Sun L, Ji J. Evaluation of the anti-inflammatory activities of tanshinones isolated from Salvia miltiorrhiza var. alba roots in THP-1 macrophages. J Ethnopharmacol. 2016;188:193–9.CrossRefGoogle Scholar
  31. 31.
    Clegg DJ, Gemert M. Determination of the reference dose for chlorpyrifos: proceedings of an expert panel. J Toxicol Environ Health B Crit Rev. 1999;2(3):211–55.CrossRefGoogle Scholar
  32. 32.
    Dorato MA, Engelhardt JA. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). Regul Toxicol Pharmacol. 2005;42:265–74.CrossRefGoogle Scholar
  33. 33.
    Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27–31.CrossRefGoogle Scholar
  34. 34.
    Bae J-W, Kim D-H, Lee W-W, Kim H-Y, Son C-G. Characterizing the human equivalent dose of herbal medicines in animal toxicity studies. J Ethnopharmacol. 2015;162:1–6.CrossRefGoogle Scholar
  35. 35.
    Blanchard OL, Smoliga JM. Translating dosages from animal models to human clinical trials--revisiting body surface area scaling. FASEB J. 2015;29:1629–34.CrossRefGoogle Scholar
  36. 36.
    Park H, Hwang Y-H, Ma JY. Single, repeated dose toxicity and genotoxicity assessment of herb formula KIOM2012H. Integr Med Res. 2017;6:361–71.CrossRefGoogle Scholar
  37. 37.
    Cha E, Lee J, Lee S, Park M, Song I, Son I, et al. A 4-week repeated dose oral toxicity study of Mecasin in Sprague-Dawley rats to determine the appropriate doses for a 13-week, repeated toxicity test. Aust J Pharm. 2015;18:45–50.Google Scholar
  38. 38.
    Lee MJ, Kim MJ, Park Y-C, Choi JJ, Jin M, Jung IC. A thirteen-week oral toxicity study of so-ochim-tang-gami-bang, a traditional Korean medicine, in Sprague-Dawley rats. J Ethnopharmacol. 2018;213:26–30.CrossRefGoogle Scholar
  39. 39.
    Yu S-Y, OuYang H-T, Yang J-Y, Huang X-L, Yang T, Duan J-P, et al. Subchronic toxicity studies of Radix Astragali extract in rats and dogs. J Ethnopharmacol. 2007;110:352–5.CrossRefGoogle Scholar
  40. 40.
    Tannenbaum C, Sheehan NL. Understanding and preventing drug–drug and drug–gene interactions. Expert Rev Clin Pharmacol. 2014;7:533–44.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Liver and Immunology Research CenterOriental Medical Collage of Daejeon UniversityDaejeonRepublic of Korea
  2. 2.Department of Internal MedicineDaejeon St. Mary’s Hospital of Catholic UniversityDaejeonRepublic of Korea

Personalised recommendations